EI
ADMA icon

EAM Investors’s ADMA Biologics ADMA Stock Holding History

EAM Investors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-235,813
Closed -$4.04M – 250
2024
Q4 		$4.04M Sell
235,813
-36,821
-14% -$693K 0.57% 82
2024
Q3 		$5.45M Sell
272,634
-102,343
-27% -$1.59M 0.81% 19
2024
Q2 		$4.19M Sell
374,977
-247,109
-40% -$2.07M 0.68% 44
2024
Q1 		$4.11M Buy
+622,086
New +$3.4M 0.64% 56
2023
Q4 		– Sell
-967,146
Closed -$3.46M – 237
2023
Q3 		$3.46M Buy
967,146
+83,304
+9% +$321K 0.67% 21
2023
Q2 		$3.26M Sell
883,842
-151,910
-15% -$563K 0.6% 35
2023
Q1 		$3.43M Sell
1,035,752
-713,846
-41% -$2.47M 0.67% 21
2022
Q4 		$6.79M Buy
1,749,598
+322,438
+23% +$995K 1.41% 1
2022
Q3 		$3.47M Buy
1,427,160
+179,024
+14% +$429K 0.75% 16
2022
Q2 		$2.47M Buy
+1,248,136
New +$2.46M 0.6% 41

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

EAM Investors's ADMA Position: Q1 2025 in Review

EAM Investors sold out of ADMA Biologics (ADMA) in Q1 2025, closing a stake of 235,813 shares — an estimated $4.04M sold.

EAM Investors first reported a position in ADMA in Q2 2022 and held it in 10 quarters. The position peaked at $6.79M in Q4 2022. 347 funds tracked by Wall St. Rank hold ADMA as of Q1 2025.

  • EAM Investors reported no remaining ADMA Biologics position as of Q1 2025 after selling out during the quarter.
  • EAM Investors sold 235,813 ADMA Biologics shares in Q1 2025, an estimated $4.04M.
  • EAM Investors first reported a position in ADMA Biologics in Q2 2022 and held it in 10 quarters.
  • EAM Investors's ADMA Biologics position peaked at $6.79M in Q4 2022.
  • 347 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2025.

Based on EAM Investors's 13F filing for Q1 2025, filed 13 May 2025.